Adverse effects from<unk>  are similar to placebo, except for rare nausea, common cold-like symptoms, and photosensitivity. It does not increase the risk of diarrhea. No significant difference exists in the occurrence of hypoglycemia between placebo and<unk> . In those taking sulphonylureas, the risk of low blood sugar is increased. The existence of rare case reports of kidney failure and hypersensitivity reactions is noted in the United States prescribing information, but a causative role for<unk>  has not been established. Several postmarketing reports of pancreatitis (some fatal) have been made in people treated with<unk>  and other DPP-4 inhibitors, and the U.S. package insert carries a warning to this effect, although the causal link between<unk>  and pancreatitis has not yet been fully substantiated. One study with lab rats published in 2009 concluded that some of the possible risks of pancreatitis or pancreatic cancer may be reduced when it is used with metformin. However, while DPP-4 inhibitors showed an increase in such risk factors, as of 2009, no increase in pancreatic cancer has been reported in individuals taking DPP-4 inhibitors. In 2015, the U.S. Food and Drug Administration (FDA) added a new warning and precaution about the risk of "severe and disabling" joint pain to the labels of all DPP-4 inhibitor medicines.
Sitagliptin
Linagliptin
Vildagliptin
Saxagliptin
Liraglutide
Exenatide
Pioglitazone
Canagliflozin